FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385753152> ?p ?o ?g. }

• W4385753152 endingPage "113289" @default.
• W4385753152 startingPage "113289" @default.
• W4385753152 abstract "The definition of hyperprogressive disease (HPD) is controversial in the literature and has not been widely described in melanoma. The aim of this study was to determine whether the concept of HPD applies to patients treated for advanced melanoma, using a definition with a simple, reproducible criterion, and to determine whether it is possible to identify predictive factors for HPD.This was a retrospective analysis on a prospective cohort. The data were extracted from MelBase, a French prospective, multicentre cohort of adult patients with advanced melanoma. The patients, following informed consent, were treated prospectively with anti-PD1, ipilimumab+nivolumab, BRAF/MEKi, or chemotherapy, 1st line or thereafter. HPD was defined, within 3 months following the start of the treatment, with the help of a clinical and biological criterion using Response Evaluation Criteria in Solid Tumours, Eastern Cooperative Oncology Group Performance Score, and lactate dehydrogenase.The occurrence of HPD in the 4 groups was as follows (numbers of patients out of the total number): anti-PD1 98/1004 (10%), ipilumumab +nivolumab 19/327 (6%), targeted therapy 31/751 (4%), and chemotherapy 40/397 (10%). In the anti programmed cell death protein 1 (APD1) group, the relevant risk factors for HPD were: more than 3 metastatic sites (p = 0.03) and liver metastasis (p < 0.001).This data, thanks to relevant clinical and biological criteria feasible in daily practice, supports the presence of a subgroup whose disease deteriorates rapidly during mono-immunotherapy. Also observed with other treatments, HPD could be the consequence of a natural and aggressive evolution of the disease, alleviated by strong-acting treatments." @default.
• W4385753152 created "2023-08-12" @default.
• W4385753152 creator A5007002871 @default.
• W4385753152 creator A5011746123 @default.
• W4385753152 creator A5014376121 @default.
• W4385753152 creator A5025478490 @default.
• W4385753152 creator A5029900243 @default.
• W4385753152 creator A5073133195 @default.
• W4385753152 creator A5077421764 @default.
• W4385753152 date "2023-11-01" @default.
• W4385753152 modified "2023-10-17" @default.
• W4385753152 title "Hyperprogression in advanced melanoma is not restricted to immunotherapy" @default.
• W4385753152 cites W2554618897 @default.
• W4385753152 cites W2588078993 @default.
• W4385753152 cites W2601621622 @default.
• W4385753152 cites W2605497049 @default.
• W4385753152 cites W2761936165 @default.
• W4385753152 cites W2799838772 @default.
• W4385753152 cites W2883447733 @default.
• W4385753152 cites W2891266481 @default.
• W4385753152 cites W2891951654 @default.
• W4385753152 cites W2904738611 @default.
• W4385753152 cites W2912723708 @default.
• W4385753152 cites W2914258217 @default.
• W4385753152 cites W2943875279 @default.
• W4385753152 cites W2947818354 @default.
• W4385753152 cites W2975954086 @default.
• W4385753152 cites W2987614176 @default.
• W4385753152 cites W2989724722 @default.
• W4385753152 cites W2989826853 @default.
• W4385753152 cites W3009008277 @default.
• W4385753152 cites W3010976613 @default.
• W4385753152 cites W3048778945 @default.
• W4385753152 cites W3063269293 @default.
• W4385753152 cites W3084555372 @default.
• W4385753152 cites W3103602933 @default.
• W4385753152 cites W3136041828 @default.
• W4385753152 cites W3137983189 @default.
• W4385753152 cites W3151754693 @default.
• W4385753152 cites W3186971878 @default.
• W4385753152 doi "https://doi.org/10.1016/j.ejca.2023.113289" @default.
• W4385753152 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37690179" @default.
• W4385753152 hasPublicationYear "2023" @default.
• W4385753152 type Work @default.
• W4385753152 citedByCount "0" @default.
• W4385753152 crossrefType "journal-article" @default.
• W4385753152 hasAuthorship W4385753152A5007002871 @default.
• W4385753152 hasAuthorship W4385753152A5011746123 @default.
• W4385753152 hasAuthorship W4385753152A5014376121 @default.
• W4385753152 hasAuthorship W4385753152A5025478490 @default.
• W4385753152 hasAuthorship W4385753152A5029900243 @default.
• W4385753152 hasAuthorship W4385753152A5073133195 @default.
• W4385753152 hasAuthorship W4385753152A5077421764 @default.
• W4385753152 hasConcept C121608353 @default.
• W4385753152 hasConcept C126322002 @default.
• W4385753152 hasConcept C141071460 @default.
• W4385753152 hasConcept C143998085 @default.
• W4385753152 hasConcept C167135981 @default.
• W4385753152 hasConcept C188816634 @default.
• W4385753152 hasConcept C2776694085 @default.
• W4385753152 hasConcept C2777658100 @default.
• W4385753152 hasConcept C2777701055 @default.
• W4385753152 hasConcept C2779013556 @default.
• W4385753152 hasConcept C2780030458 @default.
• W4385753152 hasConcept C2781433595 @default.
• W4385753152 hasConcept C502942594 @default.
• W4385753152 hasConcept C71924100 @default.
• W4385753152 hasConcept C72563966 @default.
• W4385753152 hasConceptScore W4385753152C121608353 @default.
• W4385753152 hasConceptScore W4385753152C126322002 @default.
• W4385753152 hasConceptScore W4385753152C141071460 @default.
• W4385753152 hasConceptScore W4385753152C143998085 @default.
• W4385753152 hasConceptScore W4385753152C167135981 @default.
• W4385753152 hasConceptScore W4385753152C188816634 @default.
• W4385753152 hasConceptScore W4385753152C2776694085 @default.
• W4385753152 hasConceptScore W4385753152C2777658100 @default.
• W4385753152 hasConceptScore W4385753152C2777701055 @default.
• W4385753152 hasConceptScore W4385753152C2779013556 @default.
• W4385753152 hasConceptScore W4385753152C2780030458 @default.
• W4385753152 hasConceptScore W4385753152C2781433595 @default.
• W4385753152 hasConceptScore W4385753152C502942594 @default.
• W4385753152 hasConceptScore W4385753152C71924100 @default.
• W4385753152 hasConceptScore W4385753152C72563966 @default.
• W4385753152 hasLocation W43857531521 @default.
• W4385753152 hasLocation W43857531522 @default.
• W4385753152 hasOpenAccess W4385753152 @default.
• W4385753152 hasPrimaryLocation W43857531521 @default.
• W4385753152 hasRelatedWork W2800160190 @default.
• W4385753152 hasRelatedWork W2899127460 @default.
• W4385753152 hasRelatedWork W2973740076 @default.
• W4385753152 hasRelatedWork W2976744492 @default.
• W4385753152 hasRelatedWork W3027051390 @default.
• W4385753152 hasRelatedWork W3043703771 @default.
• W4385753152 hasRelatedWork W4236421112 @default.
• W4385753152 hasRelatedWork W4241093956 @default.
• W4385753152 hasRelatedWork W4313890856 @default.
• W4385753152 hasRelatedWork W3108601240 @default.
• W4385753152 hasVolume "193" @default.

• next